Diagnostic Accuracy of a Novel Point of Care High-Sensitivity Troponin Assay in the Prehospital Environment
Abstract
OBJECTIVE: To evaluate the diagnostic accuracy of a novel point of care (POC) high-sensitivity troponin (hs-cTn) assay, used alone or incorporated within validated decision aids, for acute myocardial infarction (AMI) in the prehospital setting.
METHODS: A pre-specified secondary analysis of the Prehospital Evaluation of Sensitive Troponin (PRESTO) prospective diagnostic accuracy study, conducted in four ambulance services and 12 Emergency Departments (EDs; February 2019-March 2020). Paramedics included consenting adults with suspected AMI and no other reason for conveyance. Clinical data and venous blood were collected at the scene, and samples conveyed to hospital with participants. Plasma samples were later analyzed for hs-cTn using a novel POC hs-cTn assay (Abbott Point of Care i-STAT hs-TnI). The target condition was an adjudicated index diagnosis of type 1 AMI.
RESULTS: Of 817 consenting participants, 704 were eligible for inclusion in this analysis, with type 1 AMI occurring in 89 (12.6%). At the limit of detection (< 2 ng/L), POC hs-cTn had 100.0% sensitivity (95% CI 95 9%-100.0%) but only 4.6% specificity (95% CI 3.1%-6.5%). A Troponin-only Manchester Acute Coronary Syndromes (T-MACS) very-low risk outcome identified 134 (19.7%) patients for non-conveyance with 98.9% sensitivity (95% CI 94.9%-100.0%), 99.3% negative predictive value (NPV, 95% CI 95.0%-99.9%), and 22.5% specificity (95% CI 19.2%-26.1%). A low-risk modified HEART score identified 150 (22.0%) patients…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 817 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.